About: Drozitumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets (TRAIL), whose receptors are found on the surface of many types of malignant cells. Drozitumab was developed by Genentech. Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.

Property	Value
dbo:abstract	دروزيتوماب هو جسم مضاد وحيد النسيلة مصمم لعلاج السرطان طورته . (ar) Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets (TRAIL), whose receptors are found on the surface of many types of malignant cells. Drozitumab was developed by Genentech. Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response. (en)
dbo:casNumber	912628-39-8
dbo:fdaUniiCode	SQ67484MA7
dbo:kegg	D09888
dbo:wikiPageID	33023947 (xsd:integer)
dbo:wikiPageLength	2378 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1002569503 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Non-small_cell_lung_cancer dbr:Death_receptor_5 dbc:Abandoned_drugs dbr:Colorectal_cancer dbr:Genentech dbr:Phase_II_trial dbr:Non-Hodgkin_lymphoma dbc:Monoclonal_antibodies dbr:Chondrosarcoma dbr:Tumour_Necrosis_Factor_Related_Apoptosis-inducing_Ligand
dbp:atcPrefix	none (en)
dbp:c	6334 (xsd:integer)
dbp:casNumber	912628 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	9792 (xsd:integer)
dbp:kegg	D09888 (en)
dbp:mabType	mab (en)
dbp:n	1700 (xsd:integer)
dbp:o	2000 (xsd:integer)
dbp:s	42 (xsd:integer)
dbp:source	u (en)
dbp:target	dbr:Death_receptor_5
dbp:type	mab (en)
dbp:unii	SQ67484MA7 (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	458638503 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Monoclonal-antibody-stub dbt:Monoclonals_for_tumors
dcterms:subject	dbc:Abandoned_drugs dbc:Monoclonal_antibodies
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459
rdfs:comment	دروزيتوماب هو جسم مضاد وحيد النسيلة مصمم لعلاج السرطان طورته . (ar) Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets (TRAIL), whose receptors are found on the surface of many types of malignant cells. Drozitumab was developed by Genentech. Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response. (en)
rdfs:label	دروزيتوماب (ar) Drozitumab (en)
owl:sameAs	freebase:Drozitumab yago-res:Drozitumab wikidata:Drozitumab dbpedia-ar:Drozitumab https://global.dbpedia.org/id/4j27X
prov:wasDerivedFrom	wikipedia-en:Drozitumab?oldid=1002569503&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Drozitumab
is dbo:wikiPageWikiLink of	dbr:C6334H9792N1700O2000S42 dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Dr–Dy
is foaf:primaryTopic of	wikipedia-en:Drozitumab